Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the U.S. Government Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the U.S. Government

Cassava Sciences Appoints Three New Members to its Board of Directors

Annovis Bio

Anavex Life Sciences

Biogen

INmune Bio Inc

Eli Lilly

Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anavex's blarcamesine, Cyclo Therapeutics Trappsol Cyclo, Green Valley's GV-971, aromatherapy, and panax ginseng not only inhibit the formation of oxidants but scavenge them and reverse part of their damage.

Alzheimer's Disease Drug Development: Another Lost Year

Cassava Sciences is a biotech company focused on developing treatments for Alzheimer's disease with its lead drug candidate, Simufilam. The company has faced allegations of data manipulation and misconduct, but no concrete evidence has been found to support these claims. The Phase 2 data for Simufilam showed potential cognitive benefits in patients with mild AD, but the results were inconsistent and had several limitations.

Cassava Sciences: Likely Potential Opportunity From Phase 3 Readout Next Year

Archer Aviation

Arqit Quantum Inc

Guess?

General Motors

Kura Sushi USA

Petco Health and Wellness

Although the general concept of stock picks for contrarian investors may be universally appealing, when it comes to the most extreme examples, most investors should probably stay away. Basically, while the rewards for when the stars align can be enormously high, they rarely align.

7 High-Risk, High-Reward Stocks for the Extreme Contrarian

Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's. Over 1,900 patients randomized in on-going Phase 3 trials.

Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results

AUSTIN, Texas, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced the completion of patient enrollment in a pair of Phase 3 trials to evaluate the safety and efficacy of oral simufilam versus placebo in Alzheimer's disease dementia.

Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer's Disease

Stocks often lose much of their value as a result of controversies. Cassava Sciences is facing a raft of serious allegations from numerous parties.

1 Big Red Flag to Fear When a Stock Is Down

Cassava Sciences' stock is highly disputed due to conflicting opinions on the science behind its drug candidate, but outside research supports its apparent drug effect. Biomarkers show strong reductions in patients treated with simufilam, indicating potential efficacy in Alzheimer's disease. The reduction of NfL values over six months is similar to what led to the accelerated approval of Qalsody for ALS.

Cassava Sciences: My Bullish Take On Biomarkers And CTAD Data

AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced a potentially significant safety finding based on interim magnetic resonance imaging (MRI) brain data from Alzheimer's patients who are enrolled in a Phase 3 clinical trial of simufilam. The MRI data suggest simufilam is not associated with treatment-emergent amyloid-related imaging abnormalities, or ARIA. MRIs were all analyzed for ARIA by board-certified neuroradiologists.

MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)

AMC Entertainment

BioNTech SE

Charter Communications

Coinbase

Office Depot

Warner Bros Discovery Inc

One of the big slogans favored by CNBC pundit Jim Cramer is, “There's always a bull market somewhere.” I believe that's true.

7 Stocks That Are Heading for a Train Wreck

LOS ANGELES, CA / ACCESSWIRE / October 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of the securities laws.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the Firm

Big problems appear to be getting worse for Cassava Sciences (NASDAQ: SAVA ). The clinical-stage biotech company is a former favorite among retail investors.

SAVA Stock Continues to Plunge on Misconduct Allegations

LOS ANGELES, CA / ACCESSWIRE / October 16, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of the securities laws.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the Firm

The controversy about alleged data manipulation related to simufilam was stirred up again by a leaked report. Cassava's response noted that the report from CUNY didn't make any findings of data manipulation.

Why Cassava Sciences Stock Is Tanking Today

Cassava Sciences (NASDAQ: SAVA ) stock was hit hard after the market close yesterday following the publication of a Science article that released the details on a report published by the City University of New York (CUNY). The report accused Cassava collaborator and CUNY faculty member Hoau-Yan Wang of scientific misconduct, including image manipulation.

SAVA Stock Alert: Cassava Sciences Addresses Leaked Report

Cassava Sciences Inc has denied data manipulation after a probe into conduct over its Alzheimer's drug research was leaked yesterday, sending its shares spiralling lower.   Shares of Cassav were down nearly 21% on Friday morning at $13.97.

Cassava Sciences slumps after leaked report claims 'egregious misconduct' over Alzheimer's drug

Shares of biotech company Cassava Sciences Inc. were slammed in extended trading Thursday, after the publication Science reported that an investigation accused a neuroscientist who often collaborated with the company of “long-standing and egregious misconduct” in data management and record keeping that raised serious questions about his research.

Cassava shares plummet after investigation accuses researcher of ‘egregious misconduct'

Cassava Sciences Inc has denied data manipulation after a probe into conduct over its Alzheimer's drug research was leaked yesterday, sending its shares into a spiral.   The company's share price on NASDAQ dropped 29.30% on pre-market trades to a nadir of US$8.25 before settling by 20:00 local time, after closing at US$17.56 yesterday.

Cassava Sciences slumps after leak claims “egregious misconduct”

Cassava Sciences (NASDAQ: SAVA) stock price will be in the spotlight on Friday after the shares crumbled by over 38% in the extended hours. The shares crashed by more than 76% from the all-time high and moved to the lowest level since January 2021.

Cassava Sciences: SAVA stock plot thickens, short interest jumps

AUSTIN, Texas, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today issued the following statement regarding an internal report purportedly prepared by City University of New York (CUNY). This report was leaked to the press. The leak of the CUNY report was preceded by a 40% increase in short selling activity in the stock of Cassava Sciences.

Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press

The Alzheimer's Disease space is highly volatile, with stock prices reacting to positive or negative data from other companies in the sector. Cassava Sciences, Inc. experienced a correction after initial gains, highlighting the need for caution in the Alzheimer's space. Concerns were raised about the validity of Cassava's phase 2 trial, including participant bias, dropout bias, and the lack of a p-value.

Cassava Sciences: Unconvincing Open Label Studies, Upcoming Phase 3, Risky AD Bet

A rash of insider buying helped buoy the clinical-stage biotech's stock. Cassava said it had completed the enrollment of a phase 3 trial for an Alzheimer's disease drug.

Why Shares of Cassava Sciences Soared This Week

AUSTIN, Texas, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer's disease dementia, today announced that Remi Barbier, President & Chief Executive Officer, is invited to present at the Jefferies Biotech CNS/Neuro Summit in New York on Wednesday, October 11, 2023 at 10:30am ET. A live webcast and archived replay will also be available.

Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY

Cassava Sciences (NASDAQ: SAVA) stock price has crawled back this week after the company moved on with its Alzheimer's drug trial. The shares, which have been in a freefall for months, jumped to a high of $19.50, a few points above this month's low of $16.45.

Cassava Sciences (SAVA) stock price forms a bullish pattern: is it a buy?

AUSTIN, Texas, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced the completion of patient enrollment in a pivotal Phase 3 clinical trial. Eight hundred four (804) Alzheimer's patients are enrolled in this 12-month trial. A second Phase 3 clinical trial with a target enrollment of approximately 1,100 patients is expected to complete patient enrollment in Q4 2023. Both on-going Phase 3 clinical trials are evaluating the safety and efficacy of oral simufilam in patients with Alzheimer's disease dementia.

News for Cassava Sciences Inc Stock (SAVA)